lsd1/kdm1 isoform lsd1+8a contributes to neural differentiation in small cell lung cancer
Clicks: 107
ID: 243782
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
107 views
8 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #40 of 40 articles by views in addictive behaviors reports
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by rapid progression. The mechanisms that lead to a shift from initial therapeutic sensitivity to ultimate therapeutic resistance are poorly understood. Although the SCLC genomic landscape led to the discovery of promising agents targeting genetic alterations that were already under investigation, results have been disappointing. Achievements in targeted therapeutics have not been observed for over 30 years. Therefore, the underlying disease biology and novel targets urgently require a better understanding. Epigenetic regulation is deeply involved in the cellular plasticity that could shift tumor cells to the malignant phenotype. We have focused on a histone modifier, LSD1, that is overexpressed in SCLC and is a potent therapeutic target. Interestingly, the LSD1 splice variant LSD1+8a, the expression of which has been reported to be restricted to neural tissue, was detected and was involved in the expression of neuroendocrine marker genes in SCLC cell lines. Cells with high expression of LSD1+8a were resistant to CDDP and LSD1 inhibitor. Moreover, suppression of LSD1+8a inhibited cell proliferation, indicating that LSD1+8a could play a critical role in SCLC. These findings suggest that LSD1+8a should be considered a novel therapeutic target in SCLC.
| Reference Key |
jotatsu2017biochemistrylsd1/kdm1
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Takanobu Jotatsu;Shigehiro Yagishita;Ken Tajima;Fumiyuki Takahashi;Kaoru Mogushi;Moulid Hidayat;Aditya Wirawan;Ryo Ko;Ryota Kanemaru;Naoko Shimada;Keiko Mitani;Tsuyoshi Saito;Kazuya Takamochi;Kenji Suzuki;Shinji Kohsaka;Shinya Kojima;Hiroshi Mukae;Kazuhiro Yatera;Kazuhisa Takahashi |
| Journal | addictive behaviors reports |
| Year | 2017 |
| DOI |
10.1016/j.bbrep.2016.11.015
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.